Human embryonic stem cells: towards therapies for cardiac disease. Derivation of a Dutch human embryonic stem cell line

van de Stolpe, Anja; van De Brink, Stieneke; van Rooijen, Marga; Ward-van Oostwaard, Dorien; van Inzen, Wouter; Slaper-Cortenbach, Ineke; Fauser, Bart; van den Hout, Nijske; Weima, Sjerp; Passier, Robert; Smith, Nigel; Dening, Chris; Mummery, Christine
October 2005
Reproductive BioMedicine Online (Reproductive Healthcare Limited;Oct2005, Vol. 11 Issue 4, p476
Academic Journal
Cell transplantation is being discussed as a potential therapy for multiple disorders caused by loss or malfunction of single or at most a few cell types. These include diabetes. Parkinson's disease and myocardial infarction or cardiac failure. However, it is not yet clear whether cells from adult tissues ('adult stem cells') or embryos ('embryonic stem cells') will prove to be the most appropriate replacement cells; most likely, each disease will have its own preferred source. This study presents the background to this discussion and the current state of research in replacement of cardiac tissue, with focus on recent developments using human embryonic stem cells. It also describes a new human embryonic stem cell (HESC) line, NLHESCI. the first to be derived in the Netherlands, and shows that it forms cardiac cells in a manner comparable with that of hES2 and hES3 cells grown in the same laboratory.


Related Articles

  • A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. Blin, Guillaume; Nury, David; Stefanovic, Sonia; Tui Neri; Guillevic, Oriane; Brinon, Benjamin; Bellamy, Valérie; Rücker-Martin, Catherine; Barbry, Pascal; Bel, Alain; Bruneval, Patrick; Cowan, Chad; Pouly, Julia; Mitalipov, Shoukhrat; Gouadon, Elodie; Binder, Patrice; Hagège, Albert; Desnos, Michel; Renaud, Jean-François; Menasché, Philippe // Journal of Clinical Investigation;Apr2010, Vol. 120 Issue 4, p1125 

    Cell therapy holds promise for tissue regeneration, including in individuals with advanced heart failure. However, treatment of heart disease with bone marrow cells and skeletal muscle progenitors has had only marginal positive benefits in clinical trials, perhaps because adult stem cells have...

  • Human Embryonic Stem Cell-Derived Cardiomyocytes for Heart Therapies. Chung Wah Siu; Moore, Jennifer C.; Li, Ronald A. // Cardiovascular & Haematological Disorders - Drug Targets;Jun2007, Vol. 7 Issue 2, p145 

    Cardiovascular diseases remain the leading cause of mortality and morbidity worldwide. Despite substantial improvements in acute management, survivors of myocardial infarction often progress to heart failure. Since adult cardiomyocytes (CMs) do not regenerate, their loss permanently compromises...

  • Human embryonic stem cell transplantation to repair the infarcted myocardium. Leor, Jonathan; Gerecht, Sharon; Cohen, Smadar; Miller, Liron; Holbova, Radka; Ziskind, Anna; Shachar, Michal; Feinberg, Micha S.; Guetta, Esther; Itskovitz-Eldor, Joseph // Heart;Oct2007, Vol. 93 Issue 10, p1278 

    9Objective: To test the hypothesis that human embryonic stem cells (hESCs) can be guided to form new myocardium by transplantation into the normal or infarcted heart, and to assess the influence of hESC-derived cardiomyocytes (hESCMs) on cardiac function in a rat model of myocardial infarction...

  • Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Laflamme, Michael A.; Chen, Kent Y.; Naumova, Anna V.; Muskheli, Veronica; Fugate, James A.; Dupras, Sarah K.; Reinecke, Hans; Chunhui Xu; Hassanipour, Mohammad; Police, Shailaja; O'Sullivan, Chris; Collins, Lila; Yinhong Chen; Minami, Elina; Gill, Edward A.; Ueno, Shuichi; Chun Yuan; Gold, Joseph; Murry, Charles E. // Nature Biotechnology;Sep2007, Vol. 25 Issue 9, p1015 

    Cardiomyocytes derived from human embryonic stem (hES) cells potentially offer large numbers of cells to facilitate repair of the infarcted heart. However, this approach has been limited by inefficient differentiation of hES cells into cardiomyocytes, insufficient purity of cardiomyocyte...

  • Shortcuts to making cardiomyocytes. Huansheng Xu; Yi, B. Alexander; Chien, Kenneth R. // Nature Cell Biology;Mar2011, Vol. 13 Issue 3, p191 

    The adult human heart lacks sufficient regenerative capacity to recover after a myocardial infarction. Cell-based therapy has emerged as a potential treatment for the failing heart; however, a key issue for the success of future cell-based therapies is the ability to obtain patient-specific...

  • Strategies for directing the differentiation of stem cells into the cardiomyogenic lineage in vitro. Heng, Boon Chin; Haider, Husnain Kh; Sim, Eugene Kwang-Wei; Cao, Tong; Ng, Soon Chye // Cardiovascular Research;Apr2004, Vol. 62 Issue 1, p34 

    Most studies on stem cell transplantation therapy on myocardially infarcted animal models and phase-I human clinical trials have focused on the use of undifferentiated stem cells. There is a strong possibility that some degree of cardiomyogenic differentiation of stem cells in vitro prior to...

  • Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions. Cao, Nan; Liang, He; Huang, Jijun; Wang, Jia; Chen, Yixiong; Chen, Zhongyan; Yang, Huang-Tian // Cell Research;Sep2013, Vol. 23 Issue 9, p1119 

    Cardiovascular progenitor cells (CVPCs) derived from human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), hold great promise for the study of cardiovascular development and cell-based therapy of heart diseases, but...

  • ES cells for troubled hearts. Rubart, Michael; Field, Loren J. // Nature Biotechnology;Sep2007, Vol. 25 Issue 9, p993 

    The article presents a study that investigates the benefits of cardiomyocytes derived from human embryonic stem cells in rat models of myocardial infarction. Using echocardiography and magnetic resonance imaging, modest decreases in cardiac pump function were observed after ischemia/reperfusion...

  • Cell therapy in myocardial infarction: emphasis on the role of MRI. Yuxiang Ye; Bogaert, Jan // European Radiology;Mar2008, Vol. 18 Issue 3, p548 

    Despite tremendous progress in myocardial infarct (MI) treatment, mortality rates remain substantial. Permanent loss of cardiomyocytes after ischemic injury, results in irreversible loss of myocardial contractility, reduction in ventricular performance, and may initiate the development of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics